Three Cases of Hereditary Hemorrhagic Telangiectasia Treated with Bevacizumab.
10.3342/kjorl-hns.2016.59.8.613
- Author:
Minhyung LEE
1
;
Pona PARK
;
Daewoo KIM
;
Hong Ryul JIN
Author Information
1. Department of Otorhinolaryngology-Head and Neck Surgery, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. doctorjin@daum.net
- Publication Type:Case Report
- Keywords:
Bevacizumab;
Epistaxis (125);
Hereditary hemorrhagic telangiectasia
- MeSH:
Anemia, Iron-Deficiency;
Bevacizumab*;
Cautery;
Epistaxis;
Hemorrhage;
Humans;
Korea;
Quality of Life;
Telangiectasia, Hereditary Hemorrhagic*;
Telangiectasis;
Vascular Endothelial Growth Factor A
- From:Korean Journal of Otolaryngology - Head and Neck Surgery
2016;59(8):613-619
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hereditary hemorrhagic telangiectasia (HHT) is a hereditary, autosomal dominant, vascular dysplasia characterized by mucocutaneous telangiectasia, epistaxis, gastrointestinal bleeding, and iron deficiency anemia. Epistaxis in HHT is a recurrent and debilitating symptom, which is difficult to manage. Many methods have been tried with little success. Bevacizumab (Avastin®), a VEGF inhibitor, has been recently tried intranasally or systemically to control the recurrent epistaxis. We report three patients with HHT who were treated with intranasal bevacizumab application together with cauterization. In all three patients, recurrent epistaxis decreased considerably with improvement in quality of life. Here we describe the application methods, treatment results, and complications with literature review. We believe that this is the first report of treating epistaxis in HHT with intranasal application of bevacizumab in South Korea.
